Classic hallucinogens are serotonin 5-HT~2~ receptor agonists {#S1}
=============================================================

Classic hallucinogens (CH) are powerful psychoactive substances that are categorized into two broad chemotype classes: indoleamines (including tryptamines and ergotamines) and phenylalkylamines (including phenethylamines and phenylisopropylamines; [@R118]). Prototypical CH representative of each subclass include psilocybin, a tryptamine found in several genera of mushrooms ([@R249]); lysergic acid diethylamide (LSD), an ergotamine originally derived from ergot fungi ([@R131]); mescaline, a phenethylamine found in peyote ([@R125]) and other cacti; and 2,5-dimethoxy-4-bromoamphetamine (DOB), a phenylisopropylamine (substituted amphetamine) derived solely via synthetic schemes ([@R240]). Various analogues of these compounds have been synthesized and tested for bioactivity ([@R200]; [@R240], [@R241]; [@R242]), but for the focus of this paper, we confine classification of CH to those drugs that have been characterized extensively in both nonhuman animals and in humans ([@R26]; [@R118]). For example, we do not classify novel N-benzyl substituted phenethylamine hallucinogens as CH, because their receptor and behavioral pharmacology are not fully characterized or diverge from CH ([@R199]).

The fundamental, shared pharmacological property of all CH is high affinity and agonist activity at serotonin 5-HT~2~ G protein-coupled receptor (GPCR) subtypes (5-HT~2A~, 5-HT~2B~, and 5-HT~2C~), with most binding to and stimulating 5-HT~2~ receptors at low nanomolar concentrations. However, depending on the CH examined, activities at other GPCRs have been identified, particularly other 5-HT receptors, and, most notably, 5-HT~1~ receptor subtypes ([@R198]; [@R228]). Many attempts have been made to uncover additional molecular targets of CH. For example, tryptamine hallucinogens display activity at the sigma-1 receptor, the serotonin transporter (SERT), and the vesicular monoamine transporter ([@R59]; [@R99]), but high concentrations, reaching micromolar levels, are required to elicit activity, which calls into question their contribution to psychoactive effects. Also, it was reported recently that certain substituted amphetamine hallucinogens, including 2,5-dimethoxy-4-iodoamphetamine (DOI) and DOB, bind with appreciable affinity at adrenergic GPCRs ([@R216]). However, using traditional radioligand competition binding assays, we did not replicate the observed effects at alpha-adrenergic receptors. We obtained micromolar affinity (*K*~i~) values of (±)-DOI at each of the α-adrenergic receptor subtypes we screened (α1a, α1b, α2a, α2b, and α2c; unpublished observations; data available upon request).

Most germane to the psychoactive effects of CH is that they are blocked by 5-HT~2~ antagonists in both rodents ([@R89]) and humans ([@R154]; [@R259]). It should be noted, however, that there are exceptions wherein 5-HT~2~ antagonism is insufficient to eliminate the discriminative stimulus properties of CH (e.g., psilocybin and LSD) in rodents ([@R20]; [@R263]). Clearly, pharmacodynamics and pharmacokinetics across species play an important role, and may underlie observed discrepancies ([@R45]). Nevertheless, adding to support that 5-HT~2~ receptors are the predominant mediators of CH psychoactive effects are the observations that 5-HT~2A~ knockout mice do not exhibit behaviors, such as the head-twitch response (HTR; [@R107]; [@R121]), typically elicited by CH. Also, the DOI-elicited HTR is reduced in 5-HT~2C~ receptor knockout mice ([@R47]). Collectively, it can be said with confidence that 5-HT~2~ receptors predominantly mediate the psychoactive effects of CH. Here, we focus on interrogating 5-HT~2A~, 5-HT~2B~, and/or 5-HT~2C~ receptors as the elemental GPCRs that underlie their non-addictive nature.

Results from preclinical studies and reports from experienced hallucinogen users show that classic hallucinogens have low addiction liability {#S2}
=============================================================================================================================================

One of the fascinating aspects of CH, long recognized by experienced hallucinogen users and only recently gaining traction by the broader scientific community, is that compared with most other psychoactive drugs scheduled by federal governments in the most restrictive classes (e.g., heroin in Schedule 1 and cocaine in Schedule 2), they are relatively non-addictive ([@R26]). As a caveat, we understand that there can be controversy defining what are and what are not addictive substances, including defining CH as addictive or not ([@R202]; [@R250]). Considering the DSM-5 criteria for a diagnosis of a substance-use disorder ([@R7]), we narrowly define addictive drugs as those that induce craving or an impulse to re-dose after psychoactive effects have peaked or have begun to subside. Note, this feeling and impulse is also described in the literature as "wanting" or "increased incentive salience." Experienced drug users report that CH do not produce drug craving, which is typically elicited by other psychoactives of distinct chemical classes (e.g., methamphetamine, MDPV, nicotine, alcohol, cocaine, heroin; see erowid.org). Also, although tolerance to most CH, excluding short-acting *N,N*-dimethyltryptamine (DMT; [@R253]), is evident with repeated, continuous exposure, withdrawal symptoms are generally non-existent once effects subside, distinguishing CH from most other drugs of abuse, including closely related serotonin-releasing empathogens such as 3,4-methylenedioxymethamphetamine (MDMA) that also have activity at dopamine transporters ([@R13]; [@R185]).

The relatively non-addictive characteristics of CH described by human users are recapitulated in well-controlled, preclinical animal studies, which provide reliable and conclusive evidence. Such animal studies typically employ intravenous self-administration, in which an operant response by the animal (e.g., pressing a lever) is reinforced by the delivery of a dose of drug. While intramuscular ([@R104]), inhalation ([@R48]), and oral ([@R105]) routes of administation also maintain drug-taking behavior, intravenous drug delivery is the most employed route of administration in self-administration studies, as intravenous delivery causes a rapid onset of action, facilitating learning of the association between the operant response and the psychoactive effects of the drug. Animal self-administration experiments demonstrate a very strong correlation between drugs that produce dependence in humans and those that are voluntarily consumed by laboratory animals ([@R34]; [@R110]; [@R112], [@R111]).

One of the earliest studies on the reinforcing effects of drugs using the intravenous self-administration procedure in rhesus monkeys found that no animal initiated self-injection of mesca-line either spontaneously or after one month of programmed administration, and this was apparent at doses that produced physiological and psychoactive effects such as salivation, mydriasis, pilo-erection, and apparent apprehension ([@R69]). The lack of mescaline self-administration stood in contrast to positive findings of self-administration of morphine, codeine, cocaine, amphetamine, pentobarbital, ethanol, and caffeine. A subsequent study with rhesus monkeys using 2,5-dimethoxy-4-methylamphetamine (DOM; [@R267]) provided similar results as the mescaline study. These findings have withstood the test of time, as the primary literature is virtually devoid of any accounts of self-administration of CH, suggesting that there are very limited conditions under which laboratory animals voluntarily consume CH. In one example, extreme environmental conditions were required to elicit self-administration of DMT in monkeys ([@R243]). In this study, under baseline conditions, monkeys sampled DMT but did not engage in significant or persistent self-administration. However, following several days of sensory deprivation (i.e., the absense of light and sound), two of the three monkeys consistently self-administered DMT for up to 20 days (which was the a priori imposed endpoint of the experiment). These observations were conceptualized as the DMT engendering an internal or mental perceptual window with concomitant positive reinforcing effects in the context of sensory deprivation. In a second example, various hallucinogens were substituted in monkeys that were maintained on a baseline of (±)-MDMA self-administration. Although none of the subjects consistently self-administered any of the hallucinogens tested, all of the subjects transiently and sporadically self-administered psilocybin, mescaline, and DMT at response rates that were comparable to MDMA and up to the maximum number of infusions that were available ([@R90]). These effects, however, were transient and sporadic, and clearly unlike those seen across a broad range of other psychoactive drugs. In our studies, we observed very weak reinforcing effects of psilocybin in rhesus macaque monkeys. Once responding during saline administration was procedurally manipulated to an extradorinarily low level (approximately 0.01 responses per second), some positive reinforcing effects were apparent with psilocybin (unpublished observations; data available upon request), but yet again, these effects massively pale in comparison to other drugs of abuse ([@R191]). Based on these studies, it is clear that conditions have not yet been found, despite decades of efforts, wherein CH are readily self-administered by laboratory animals. Given the very strong correlation between drugs that produce dependence in humans and those that are voluntarily consumed by laboratory animals ([@R34]; [@R110]; [@R112], [@R111]), this is among the strongest evidence for the non-addictive nature of CH.

Despite the relative absence of addictive properties, observed in well-controlled preclinical studies and reported by human users, CH can dose-dependently elevate mood and produce a strong sense of well-being, depending on mental set and environmental setting ([@R254]). In fact, many people who have taken CH report that their experiences were of the most influential and positive of their lives ([@R113]). These positive psychological effects of CH, nonetheless, do not qualify them as without risk, especially when taken without precaution, careful planning, and supervision. CH produce profound alterations in cognition and sensory perception and can produce emotional lability, fear, anxiety, and/or panic, among other adverse psychological and physiological effects. Nonetheless, if CH can elevate mood and produce a sense of well-being, why are they non-addictive?

Why are classic hallucinogens non-addictive? Focus on serotonin {#S3}
===============================================================

There are several biological possibilities to explore why CH are relatively non-addictive. For example, the long durations of action of many CH and their capacity to induce 5-HT~2A~ receptor desensitizaton ([@R164]), which causes rapid, prolonged, and profound tolerance to their psychoactive effects (i.e., tachyphalaxis), may be factors. In support of these possibilities, it is well known that long pharmacokinetic profiles, including long durations of action, can minimize abuse liability ([@R3]; [@R91]; [@R180]; [@R196]; [@R258]; [@R264]). The psychedelic effects of LSD, which persist for approximately 8--12 hours, are greatly attenuated with repeated dosing; a few days of abstinence are required before subjective effects return to pre-exposure levels ([@R19]). Thus, spacing intake of LSD is necessary, which prevents the binge-like patterns of drug consumption often seen with highly addictive substances ([@R1]; [@R222]). However, effects of DMT are inconsistent with this explanation. The hallucinogenic effects of DMT commence within two minutes of intravenous administration, and subside by 30 minutes ([@R252]). Moreover, the psychedelic effects of DMT persist with repeated administration in a single drug-taking session ([@R251]). This may generalize across some tryptamines, as a recent study shows profound tolerance in mice to two phenethylamines (DOI and 2C-T-7), but a lack of tolerance to two tryptamines (DPT and DIPT; [@R246]). Despite their differerent durations of action and capacities to induce tolerance, none of the CH mentioned above are known to produce drug craving in human users. Comparatively, re-intoxication from addictive psychoactives can be achieved quickly after their effects subside, despite long durations of action (e.g., MDMA) combined with target densitization and/or internalization and tolerance. For example, cannabinoid CB~1~ receptor downregulation is evident with prolonged cannabis use ([@R51]), but the subjective high from cannabis persists, even with tolerance and daily use. To maintain scope, this review focuses on serotonin receptor targets of CH that likely underlie their non-addictive properties.

The reinforcing and addictive effects of psychoactive drugs are primarily attributed to drug-induced changes in central dopamine function. Pointedly, the transition to addiction is mediated by increases in firing of ventral tegmental area (VTA) dopamine neurons projecting to the nucleus accumbens (NAc), which increases dopamine release in the NAc ([@R55]; [@R159]; [@R208]; [@R219]; [@R224]); all addictive drugs increase dopamine release in the NAc. Serotonin, on the other hand, plays an important modulatory role in the behavioral effects of many psychoactive drugs. Serotonin neurons originate in the raphe nuclei in the brainstem, and send strong projections to the VTA, prefrontal cortex (PFC), amygdala, hippocampus, dorsal striatum, and NAc ([@R119]). Serotonergic projections innervate cell bodies and terminals of dopamine neurons ([@R17]; [@R101]; [@R194]; [@R207]), often making direct synaptic contact ([@R128]; [@R194]), and serotonin provides tonic and phasic control of dopaminergic systems within the limbic pathway ([@R6]).

Converging results from many studies demonstrate that enhancing central serotonin release attenuates addictive behaviors ([@R188]). For example, selective stimulation of serotonergic dorsal raphe nucleus afferents to the NAc, using designer receptors exclusively activated by designer drugs (DREADDs), abolishes cocaine-elicited conditioned place preference ([@R268]). Furthermore, there is a negative relationship between the potencies of several cocaine- and amphetamine-like analogs in self-administration studies and their binding potencies as SERT inhibitors ([@R220]; [@R219]). For example, rhesus monkeys self-administer more infusions of PAL-353, which has high selectivity for releasing dopamine versus serotonin, than PAL-313, which non-selectively releases dopamine and serotonin ([@R262]). Similarly, rhesus monkeys do not self-administer PAL-287, which is relatively nonselective at releasing dopamine and serotonin, across a range of doses ([@R230]). Adding to the evidence, systemic administration of selective SERT inhibitors, which selectively increase extracellular levels of serotonin, decrease cocaine self-administration in rodents ([@R49]; [@R217]) and nonhuman primates ([@R152]). In nonhuman primates, SERT inhibitors, such as citalopram, fluoxetine, and alaproclate, attenuate the behavioral-stimulant effects of cocaine, cocaine self-administration, cocaine-induced increases in extracellular dopamine, and cocaine-induced activation of the PFC ([@R63]; [@R133]; [@R135]; [@R248]). Additional studies show that SERT inhibitors attenuate drug-induced increases in dopamine levels in rodents and nonhuman primates ([@R63]; [@R79]) and cue-induced reinstatement of extinguished cocaine-maintained lever-pressing behavior in rats ([@R12]; [@R42]). Furthermore, an early study shows that serotonin infused directly into the NAc attenuates locomotor activity stimulated by direct infusions of dopamine into the NAc ([@R150]). These studies demonstrate convincingly that serotonin opposes the effects of dopamine and attenuates the abuse-related and addictive effects of psychoactive drugs (for reviews, see [@R136]; [@R190]).

While it is well documented that serotonin attenuates the reinforcing effects of a variety of psychoactive drugs through suppression of dopamine neurotransmission, it is important to consider that there are 16 distinct serotonin receptors (not including splice variants or RNA-edited 5-HT~2C~ receptors) that are grouped into seven families: 5-HT~1~--5-HT~7~ receptors ([@R24]; [@R109]; [@R137], [@R138]). Unique serotonin receptors can facilitate, inhibit, or have no effect on dopamine neurotransmission and on the reinforcing properties of a variety of psychoactive drugs. With particular relevance to the anti-addictive properties of CH, there are a number of reported observations of opposing effects between the 5-HT~2C~ and 5-HT~2A~ receptor subtypes, with 5-HT~2A~ receptors facilitating and 5-HT~2C~ receptors suppressing dopamine neurotransmission ([@R38]; [@R68]; [@R92], 2006; [@R96]; [@R182]; [@R183]). The divergent effects of 5-HT~2A~ and 5-HT~2C~ on dopamine neurotransmission are at first consideration peculiar, since 5-HT~2~ receptor subtypes couple to the same G-proteins (e.g., Gα~q/11/12/13~) and activate the same intra-cellular signaling pathways (e.g., phospholipase C \[PLC\], mitogen-activated protein kinase, β-arrestin), with a few notable exceptions ([@R21], [@R22]; [@R52]; [@R153]; [@R234]). However, the differences observed may also be due to differences in the relative expression of 5-HT~2A~ and 5-HT~2C~ receptors across cell types and microcircuits that control unique aspects of neural function, a point discussed in greater detail in the 5-HT~2C~ sections below. Nonetheless, the differences between 5-HT~2A~ and 5-HT~2C~ modulation of dopamine neurotransmission provide a clear hypothesis for why CH, which do not provide a large spread between 5-HT~2C~ and 5-HT~2A~ receptor activation, do not induce craving. We argue that activation of 5-HT~2C~ receptors tempers the addictive liability of CH.

Considerations of 5-HT~2A~ receptor activation to addiction liability {#S4}
=====================================================================

There is a substantial body of evidence that the 5-HT~2A~ receptor facilitates dopamine neurotransmission. For example, systemic administration of DOI increases the firing rates of dopamine neurons in the VTA and induces dopamine release in the PFC, effects that are attenuated by selective antagonism of the 5-HT~2A~ receptor ([@R31]; [@R209]) or genetic deletion of the 5-HT~2A~ receptor ([@R78]; [@R141]). The preponderance of evidence for 5-HT~2A~ receptor facilitation of dopamine neurotransmission emanates from studies of the mesocortical system because of the widespread interest in serotonin modulation of this system in schizophrenia. Nevertheless, some studies examined 5-HT~2A~ receptor modulation of dopamine neurotransmission within the NAc, which is a key region in the mesolimbic dopamine pathway critical for addiction ([@R117]; [@R232]; [@R238]). In this regard, direct administration of DOI into the posterior NAc significantly increases dopamine levels locally within the NAc, effects that are blocked by 5-HT~2A~ antagonists ([@R33]; [@R266]). However, we recently showed that systemic administration of DOI in rhesus monkeys engenders only meager (∼10% increase above baseline) elevations in dopamine levels in the NAc (unpublished observations; data available upon request), and similarly, previous studies in rats show that systemic DOI does not affect dopamine release in the NAc ([@R78]). This suggests that DOI acting on additional neural systems or microcircuits suppresses the increase in dopamine neurotransmission in the NAc.

That 5-HT~2A~ receptors may contribute to drug seeking is further supported by studies employing neuroimaging, behavioral pharmacology, and genetic tools. A recent primate neuroimaging study shows that several months of cocaine self-administration increases the availability of 5-HT~2A~ receptors in the PFC, suggesting that increased 5-HT~2A~ receptor availability facilitates drug-taking behavior ([@R236]). This is supported by observations that 5-HT~2A~ knockout mice self-administer MDMA to a lesser degree than wild-type mice, and that the selective 5-HT~2A~ inverse agonist, eplivanserin, blocks cue-induced reinstatement of MDMA seeking ([@R204]). Other studies report that 5-HT~2A~ receptor antagonists attenuate the stimulatory effects of cocaine, amphetamine, MDMA, and methamphetamine on dopamine neurotransmission as well as their locomotor stimulant and interoceptive effects ([@R9]; [@R35]). Intra-VTA microinjections of 5-HT~2A~ receptor antagonists attenuate cocaine- and amphetamine-induced increases in motor activity in mice ([@R9]) and rats ([@R183]), and we showed recently that selective 5-HT~2A~ receptor antagonism attenuates the dopamine releasing and behavioral effects of amphetamine in primates ([@R189]). Systemic administration of 5-HT~2A~ receptor antagonists (including SR 46349B, M100907, and MDL 11,939), in contrast to the effects of agonists, do not alter firing rates of dopamine neurons in the VTA or dopamine release in the NAc or PFC of rodents ([@R29]; [@R73]; [@R103]; [@R209]; [@R212]). Therefore, although the 5-HT~2A~ receptor does not appear to exert a tonic influence on dopamine neuronal firing or release, agonist stimulation of this receptor enhances dopaminergic activity ([@R38]). Though, net effects may depend on specific cell types and circuits examined.

The use of reinstatement procedures provides an important complement to drug self-administration, as it is the most widely accepted model of drug relapse. As drug relapse is critically influenced by craving and withdrawal, reinstatement experiments have particular relevance for understanding the non-addictive nature of CH. Such studies show that 5-HT~2A~ receptor antagonism prevents reinstatement of drug-seeking behavior. For example, the 5-HT~2~ receptor antagonist ketanserin attenuates cue-induced reinstatement of extinguished cocaine self-administration in rats ([@R41]), and the selective 5-HT~2A~ receptor antagonist M100907 attenuates both drug- and cue-induced reinstatement of extinguished cocaine self-administration in rats ([@R96]; [@R197]). Consistent with these findings, we have shown that 5-HT~2A~ receptor antagonism attenuates cue- as well as drug-induced reinstatement of extinguished behavior that was previously maintained by cocaine in rhesus monkeys ([@R191]).

These studies suggest that selective activation of 5-HT~2A~ receptors may induce craving and/or relapse. Nevertheless, it will be critical to assess empirically the addictive or anti-addictive potential of highly selective 5-HT~2A~ agonists. A recent report shows that an analogue from the phenethylamine class of CH, (4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine (TCB-2) that has high 5-HT~2A~ agonist potency ([@R181]) reduces intracranial self-stimulation (ICSS), but does not attenuate the potentiating effects of cocaine on ICSS ([@R151]). Its activity at 5-HT~2B~ and 5-HT~2C~ receptors, however, has not been reported to our knowledge. Finally, CH may be biased agonists ([@R106]; [@R181]; [@R260]) that stabilize 5-HT~2A~ receptor active conformations that block craving. Certainly, additional studies are warranted.

Considerations of 5-HT~2B~ receptor activation to addiction liability {#S5}
=====================================================================

Owing to their low expression in the central nervous system ([@R30]; [@R85]; [@R160]; [@R170]), much less attention has been given to the potential role of 5-HT~2B~ receptors to the effects of psychoactive substances. Moreover, as prolonged activation of 5-HT~2B~ receptors on heart valve leaflets is linked to valvular heart disease ([@R142]; [@R227]; [@R229]), an impetus to develop highly-selective 5-HT~2B~ agonists has been lacking. Indeed, there is not a highly selective 5-HT~2B~ agonist probe that is a widely accepted tool of the scientific community. Thus, there are somewhat limited data regarding the contribution of 5-HT~2B~ receptor activation to psychoactive substances. Much of what is known, however, emanated predominantly from the Maroteaux laboratory. Converging data from 5-HT~2B~ receptor knockout mice and from use of 5-HT~2B~ ligands show that central 5-HT~2B~ receptors contribute to the psychomotor effects of MDMA ([@R82]), the anorexient effects of dexfenfluramine ([@R14]), and the antidepressant effects of selective serotonin reuptake inhibitors ([@R81]; [@R127]). Another recent study shows that LY266097, a selective 5-HT~2B~ antagonist, reduces basal and amphetamine-stimulated dopamine release in the NAc, and also decreases amphetamine-elicited hyperlocomotion ([@R10]), although others report that selective 5-HT~2B~ antagonists, including SB 204741, do not affect cocaine-elicited hyperlocomotion or the discriminative stimulus effects of cocaine ([@R92], [@R93]). In addition to the different neuropharmaco-logical effects of amphetamine versus cocaine, the potential discrepancies in these studies could relate to the use of different 5-HT~2B~ antagonist ligands, and consequently target selectivity or off-target liability.

Finally, Roth\'s group reported that the designer empathogen 1-(benzofuran-6-yl)propan-2-amine (6-APB), an MDMA analogue, binds with \>100-fold selectivity to the 5-HT~2B~ receptor compared to 5-HT~2A~ or 5-HT~2C~ receptors, and furthermore, 6-APB is a 5-HT~2B~ receptor agonist ([@R146]). Interestingly, 6-APB has higher affinity at 5-HT~2B~ than any other target tested, including the dopamine transporter, a primary target of addictive psychostimulants (e.g., cocaine and methamphetamine). Anecdotal reports note that 6-APB produces subjective effects similar to MDMA, but according to some, it does not produce drug craving and has a low propensity to cause physical dependence (see [bluelight.org](http://bluelight.org) and [erowid.org](http://erowid.org)). However, controlled tests of its addictive potential have not been reported. Additional studies assessing the contribution of 5-HT~2B~ receptor activation to the low addiction liability of CH are warranted.

Considerations of 5-HT~2C~ receptor activation to addiction liability: Behavioral studies {#S6}
=========================================================================================

Numerous lines of evidence from multiple laboratories show that 5-HT~2C~ receptor activation attenuates self-administration of addictive substances and also attenuates ICSS of the brain\'s primary reward circuitry, and there are a number of excellent recent reviews on the topic of 5-HT~2C~ receptor agonists for addiction and mechanisms underlying their effects ([@R66]; [@R71]; [@R76]; [@R130]; [@R134]; [@R188]). Selective agonists of the 5-HT~2C~ receptor have generally been found to recapitulate the attenuating effects of indirect serotonin agonists on behavioral models of addiction, suggesting 5-HT~2C~ receptor activation is a key molecular mechanism by which serotonin exerts its anti-addictive effects. For example, the rate-suppressing effects of both the indirect serotonin receptor agonist fenfluramine and the 5-HT~2C~ receptor agonist Ro 60-0175 in an ICSS procedure are blocked by pretreatment with the 5-HT~2C~ receptor selective antagonist SB 242084 ([@R16]). Likewise, Ro 60-0175 blocks cocaine-seeking behavior in rats, an effect completely reversed by SB 242084 ([@R40]). Acute VTA or systemic administration of a variety of relatively selective 5-HT~2C~ receptor agonists in rodents suppress the locomotor stimulant effects of cocaine ([@R60]; [@R92]; [@R95]; [@R115]), the discriminative stimulus effects of cocaine ([@R44]; [@R61]; [@R97]; [@R100]), cocaine self-administration ([@R61]; [@R97]; [@R115]), and reinstatement of cocaine seeking induced by exposure to cocaine and cocaine-associated cues ([@R40]; [@R61]; [@R97]; [@R115]; [@R195]). These findings have been extended to other classes of psychoactive drugs, including alcohol, cannabis, and nicotine ([@R130]; [@R147]; [@R178]; [@R214]; [@R269]).

In primates, recent studies show that Ro 60-0175 reduces psychostimulant effects of cocaine, cocaine self-administration, and cocaine-induced reinstatement ([@R176]; [@R231]). These effects do not appear to result from general suppression of operant responding, as the same dose of Ro 60-0175 has no effect on operant responding maintained by negative reinforcement ([@R176]). Similarly, the highly-selective 5-HT~2C~ receptor agonist lorcaserin attenuates the discriminative stimulus effects of cocaine and suppresses cocaine self-administration following acute or 14-day treatment in rhesus monkeys ([@R58]). Clinical trials assessing lorcaserin\'s ability to reduce cocaine self-administration are now underway (e.g., [ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: NCT02537873).

The hypothesis that 5-HT~2C~ receptors inhibit a variety of abuse-related effects of drugs is substantiated by the reliable finding that antagonists facilitate such effects. In rodents, systemic administration of 5-HT~2C~ receptor antagonists enhance the locomotor stimulant effects of cocaine ([@R96], [@R98]), the discriminative stimulus effects of cocaine ([@R93]), cocaine self-administration ([@R96]), and cocaine-induced reinstatement ([@R96]). Consistent findings are reported in primates, as SB 242084 increases rates of responding maintained under a fixed-interval schedule of stimulus termination, increases cocaine-primed reinstatement of cocaine self-administration, and, critically, maintains self-administration when substituted for cocaine ([@R175]). Other studies also suggest that 5-HT~2C~ antagonists themselves may be addictive substances ([@R73]; [@R77]). Finally, 5-HT~2C~ receptor knockout mice exhibit increased sensitivity to the effects of cocaine ([@R225]). Collectively, the literature is replete with evidence that activation of 5-HT~2C~ receptors inhibits addictive effects of a variety of drugs. As CH activate 5-HT~2C~ receptors, we surmise this property is an essential facet that renders CH non-addictive.

Considerations of 5-HT~2C~ receptor activation to addiction liability: Neurochemistry studies {#S7}
=============================================================================================

The most supported mechanism for the anti-addiction effects of 5-HT~2C~ activation is inhibition of mesolimbic dopamine neurons, which decreases psychostimulant-elicited dopamine release in the NAc ([@R6]; [@R39]; [@R58]; [@R74]; [@R78]; [@R97]; [@R124]; [@R134]; Manvich et al., 2012b; [@R192]; [@R225]). Evidence suggests these effects are caused by 5-HT~2C~ receptor-mediated activation of GABA neurons in the VTA, which directly inhibit VTA dopamine neuron activity ([@R37]; [@R39]; [@R75]; [@R134]). Conversely, inactivation of 5-HT~2C~ receptors by antagonists or inverse agonists increases firing rates of VTA dopamine neurons, increasing dopamine levels in the NAc ([@R73]; [@R80]). Identifying the specific neural circuitry examined in such studies, however, is important, as these observations ostensibly conflict with the conclusions from a new report about 5-HT~2C~ receptor modulation of dopamine neurotransmission ([@R265]). Specifically, using slice electrophysiology, the authors report that 5-HT~2C~ receptors expressed on dopamine neurons stimulate a significant number of them. Collectively, the data suggest that the emergent effects of 5-HT~2C~ activation on dopamine neurotransmission depend on the relative activation of 5-HT~2C~ receptors on different cell types; for example, GABA neurons innervating dopamine neurons (resulting in dopamine neuron inhibition) relative to 5-HT~2C~ receptors expressed directly on dopamine neurons (resulting in dopamine neuron activation). In support of this, in mice that express 5-HT~2C~ receptors only on dopamine VTA neurons, 5-HT~2C~ activation enhances dopamine neuron activity to a greater degree than in wild-type mice, suggesting that 5-HT~2C~ receptors on other cell types have an inhibitory effect on dopamine neurotransmission ([@R265]).

Other findings corroborate the view that 5-HT~2C~ receptor activation impacts reward circuitry via multiple mechanisms. Recent studies point to direct modulatory effects of 5-HT~2C~ receptor activation on dopamine signaling in the NAc as contributors to their anti-addiction properties, and these effects may have as much relevance for addiction treatment as the effects of 5-HT~2C~ receptors in the VTA. For example, 5-HT~2C~ receptors expressed in the NAc inhibit postsynaptic dopamine signaling by inhibiting phosphorylation of DARPP-32, independent of dopamine release ([@R50]; [@R70]). 5-HT~2C~ receptor knockout mice also provide evidence for 5-HT~2C~ negative modulation of dopamine neurotransmission in reward circuitry. 5-HT~2C~ knockout mice are more sensitive to the psychostimulant effects of amphetamine, cocaine, and GBR 12909 (another dopamine reuptake blocker) and also exhibit increased cocaine-stimulated release of dopamine in their NAc ([@R2]; [@R225]). Interestingly, the enhanced effects of cocaine on dopamine release in the NAc in 5-HT~2C~ knockout mice are not observed in the dorsal striatum ([@R225]). Similarly, amphetamine\'s effects on dopamine release in the dorsal striatum are not potentiated in 5-HT~2C~ knockout mice ([@R2]). This neural system-specific effect is recapitulated using 5-HT~2C~-selective ligands. For example, 5-HT~2C~ agonists administered systemically attenuate cocaine-stimulated dopamine release in the NAc, but not the dorsal striatum in wild-type mice ([@R74]) or in nonhuman primates ([@R176]). Also, systemic treatment with 5-HT~2C~ agonists alone reduces dopamine in the NAc, but not the dorsal striatum ([@R74]; [@R179]), and the converse effects are observed after treatment with 5-HT~2C~ antagonists or inverse agonists; that is, they increase dopamine release in the NAc, but again, they have minimal effects on dopamine release in the dorsal striatum ([@R77]). These data are confluent with the distribution of 5-HT~2C~ receptors across neural systems, as 5-HT~2C~ receptors are densely expressed in the NAc but not the dorsal striatum ([Figure 1](#F1){ref-type="fig"}). These observations suggest that post-synaptic 5-HT~2C~ receptors in the NAc may contribute strongly to the effects of selective 5-HT~2C~ agonists, administered systemically, on dopamine release in reward circuitry, a hypothesis we build in the following sections. Overall, the data provide a mechanistic rationale for the efficacy of CH, as 5-HT~2C~ agonists, to temper the rewarding effects of addictive drugs. As a recent optogenetic study showed exquisitely that dopamine cell firing in the medial forebrain bundle, including the VTA---NAc tract, is sufficient to cause a transition to addiction ([@R208]), it is clear that 5-HT~2C~ agonists have promise as tools in the treatment of addiction.

The NAc is a key site for 5-HT~2C~ receptor modulation of reward circuitry {#S8}
==========================================================================

As noted above, much of the circuitry-related data supporting 5-HT~2C~ receptor modulation of psychostimulant effects is focused on 5-HT~2C~ receptors expressed on GABA neurons of the VTA. We do not discount these findings. However, important rationale for our focus on 5-HT~2C~ receptors in the NAc are the observations that infusions of the selective 5-HT~2C~ agonist, WAY 161503, into the NAc, but not the VTA, decrease the reward-facilitating effects of cocaine ([@R151]). Moreover, infusions of the selective 5-HT~2C~ antagonist, SB 242084, into the VTA does not affect cocaine-induced dopamine release in the NAc, but when infused into the NAc, SB 242084 potentiates cocaine-induced dopamine release in the NAc ([@R192]). Also, the 5-HT~2C~ inverse agonist, SB 206553 increases basal dopamine release in the NAc when it is infused there, but not when it is infused in the VTA, suggesting 5-HT~2C~ constitutive activity in the NAc, but not VTA, modulates tonic NAc dopamine release ([@R66]; [@R193]). In summary, these data suggest that activation of NAc 5-HT~2C~ receptors negatively modulates the effects of cocaine.

Raphe nuclei send strong 5-HT projections to the NAc ([@R257]), and 5-HT~2C~ receptors are predominantly post-synaptic and excitatory ([@R11]; [@R145]), suggesting they reside on GABAergic MSN, which account for ∼90% of NAc neurons ([@R184]). Indeed, immunochemistry and neurophysiology studies show that 5-HT~2C~ receptors are expressed on MSN of the NAc ([@R54]; [@R108]; [@R235]). Furthermore, autoradiography data from mice that over-express 5-HT~2C~ receptors (while maintaining the distribution pattern of 5-HT~2C~ receptors across neural systems that is observed in wild-type mice; [@R203]) show clearly that 5-HT~2C~ receptors are densely expressed in the NAc, but not the dorsal striatum (see [Figure 1](#F1){ref-type="fig"}; which receives dopaminergic projections from substantia nigra). This is particularly intriguing when considered in the context of observations of the effects of cocaine on dopamine release in the NAc compared with the dorsal striatum. As stated earlier, 5-HT~2C~ knockout mice, relative to WT mice, show an increase in cocaine-stimulated dopamine release in the NAc, but this effect is not observed in the dorsal striatum ([@R225]). Furthermore, 5-HT~2C~ agonists administered peripherally suppress cocaine-stimulated dopamine release in the NAc, but not the dorsal striatum ([@R176]). Thus, we consider, like others ([@R193], [@R192]), that 5-HT~2C~ receptors expressed in NAc are contributing significantly to the anti-addiction effects of 5-HT~2C~ agonists, with special relevance to cocaine addiction.

Several studies show that the shell region of the NAc is associated more closely than the core with the appetitive or reinforcing effects of addictive substances ([@R15]; [@R72]; [@R143]; [@R226]; [@R237]). For example, non-contingent and self-administered cocaine preferentially increases dopamine in the NAc shell ([@R163], [@R162]; [@R211]), and a recent predictive model shows that cocaine treatment enhances the phasic signaling of dopamine neurons projecting to the NAc shell, but not to the core ([@R84]). Also, others report, more generally, that the NAc shell codes reward value ([@R233]). Furthermore, MSN of the NAc shell, specifically D1-containing MSN, send direct projections to the VTA, generating an inhibitory feedback circuit ([@R23]; [@R238]); this circuit is necessary for the integration of our 5-HT~2C~ mechanistic hypothesis, and 5-HT~2C~ regulation of NAc-VTA circuitry has been speculated ([@R94]). Interestingly, 5-HT projections to the NAc segregate in the core and shell regions; 5-HT terminals in the NAc shell are larger in diameter, contain more, large dense core vesicles, and form more symmetric contacts with dendrites ([@R36]; [@R257]). Moreover, systemic administration of 5-HT~2C~ selective agonists decrease, and inverse agonists increase, dopamine release in the NAc shell ([@R67]; [@R78]; [@R103]). Finally, immunohistochemistry results show that 5-HT~2C~ receptors are expressed at higher densities in the NAc shell, relative to the core ([@R54]). Thus, we speculate that 5-HT~2C~ receptors are expressed on D1-containing MSN of the NAc shell, and when activated, they enhance their activity, occluding effects of D1 activity, and thus increasing GABA release in the VTA. This is supported by the observations that 5-HT~2C~ receptor knockout mice show enhanced behavioral responses to the D1 receptor agonist SKF 81297 ([@R2]).

5-HT~2C~ modulation of intrinsic plasticity via inhibition of NAc Kv1.x channels: A novel hypothesized mechanism for psychostimulant addiction treatment {#S9}
========================================================================================================================================================

Based on a synthesis of what is known in the literature regarding 5-HT~2C~ receptor function, neural circuitry, and neurochemistry underlying addiction, we hypothesize that activation of 5-HT~2C~ receptors, specifically on GABAergic MSN in the NAc shell ([@R108]), inhibits Kv1.x channels, including Kv1.1, Kv1.2, and Kv1.3, leading to increased intrinsic activity (non-synaptic increases in neuronal firing capacity). Taken together with several reports that show NAc intrinsic activity is decreased by psychostimulant exposure ([@R56]; [@R108]; [@R126]; [@R139]; [@R140]; [@R270]), and germane to our hypothesis that Kv1.x channel conductance is enhanced by exposure to psychostimulants ([@R140]; [@R157]; [@R156], [@R155]), it is inferred that 5-HT~2C~ receptor activation may directly counteract effects of psychostimulants on intrinsic plasticity. Accordingly, the increase in NAc shell MSN cellular activity by 5-HT~2C~ receptor activation would directly counteract the decrease in NAc shell MSN activity caused by psychostimulants ([Figure 2](#F2){ref-type="fig"}).

Potassium Kv1.x channels ([@R53]), Kv1.1--Kv1.8, are voltage-gated channels that regulate the intrinsic activity of neurons. Kv1.x channel conductance is critical for the generation and modulation of action potentials, regulating neurotransmitter release and neural circuit excitability. Kv1.x channels open upon membrane depolarization, permitting the flow of potassium ions from within the cell, leading to restoration of the resting membrane potential. In addition, activation of Kv1.x inhibits cell-firing frequency and delays the onset of action potentials ([@R165]). Conversely, Kv1.x channel blockers prevent the flow of potassium ions, causing spontaneous depolarization and increasing, for example, action potential frequency and neurotransmitter release ([@R215]; [@R244]; [@R255]). There are several excellent reviews on Kv channel localization in the brain, their trafficking, structure, and function, and involvement in brain disease pathophysiology ([@R64]; [@R129]; [@R149]; [@R221]; [@R223]; [@R239]; [@R261]).

Several studies, using both ex vivo and in vitro cell systems show clearly that 5-HT~2C~ activation suppresses Kv1.x channels. First, 5-HT~2C~ receptors are expressed in neural systems where Kv1.x channels are also expressed ([@R64]). For example, the choroid plexuses, where 5-HT~2C~ receptor expression is dense ([@R123]; [@R168]; [@R177]), also robustly express Kv1.1 and Kv 1.3 channels ([@R247]). Application of 5-HT to choroid plexus cells abolishes potassium currents, an effect reversed by addition of the 5-HT~2C~ antagonist, mesulergine ([@R247]). Similarly, in heterologous oocyte systems expressing 5-HT~2C~ receptors and Kv1.1, Kv1.2, or Kv1.3 channels, application of 5-HT eliminates potassium generated currents from each channel ([@R5]; [@R144]). The effect of 5-HT~2C~ may be relegated to Kv1.x type channels, as 5-HT activation of 5-HT~2C~ receptors does not affect Kv3.1 channel activity ([@R5]). The exact cell signaling pathways underlying these effects remain unclear, but studies suggest 5-HT~2C~-Gα~q~-PLC signaling and activation of protein kinase C and tyrosine kinases PYK2 and Src are important contributors ([@R5]; [@R28]; [@R144]; [@R247]).

Contrary to 5-HT~2C~ receptor\'s effects on Kv1.x channels, exposure to cocaine increases potassium currents, as measured in the NAc shell. Recent studies examining NAc shell GABAergic MSN show that these effects are mediated by an increase in the activity of Kv1.2 channels, leading to a decrease in excitability and firing rate ([@R140]; [@R157]; [@R156]; [@R187]). Furthermore, exposure to cocaine for 10 consecutive days increases the expression of Kv1.2 channels ([@R156]). Importantly, the cocaine-induced depression of firing rate of MSN of the NAc shell is persistent, and decreases in the excitability of the NAc shell lead to enhanced locomotor responses and behavioral sensitization to cocaine and are associated with enhanced cocaine self-administration ([@R116]; [@R157]). Moreover, cocaine\'s inhibitory effects on MSN activity are specific to the NAc shell, with cocaine actually increasing MSN firing in the NAc core ([@R157]; [@R156]; [@R187]). Finally, overexpression of a hyperpolarizing, inwardly-rectifying potassium channel (Kir2.1) in NAc MSN enhances psychomotor effects of cocaine ([@R83]), whereas knockdown of the Kv1.1 channel blocks behavioral effects of another psychostimulant, amphetamine ([@R102]). Thus, there is a strong argument that some psychostimulant effects are mediated by alterations in intrinsic plasticity in NAc shell MSN, driven by Kv1.x currents that decrease excitability ([@R155]), and CH-mediated 5-HT~2C~ receptor activation may offset these effects ([Figure 2](#F2){ref-type="fig"}).

Caveat emptor {#S10}
=============

5-HT~2C~ receptors are expressed in several neural systems, including the frontal and cingulate cortices, that regulate impulsivity, approach, and reward behavior, and activation of these receptors impacts neural circuitry to modulate the effects of addictive drugs ([@R8]; [@R37]; [@R65]; [@R166]; [@R201]). Our hypothesis regarding 5-HT~2C~ modulation of Kv1.x channels could be extended to these other neural systems. However, to maintain scope, we have focused on the NAc shell. Despite the logic regarding 5-HT~2C~ receptors and Kv1.x channels, there are reports that 5-HT~2A~ receptor activation also decreases Kv1.x activity, specifically Kv1.5 channels in cardiac tissue ([@R57]) and Kv1.2 channels in cortical pyramidal neurons ([@R161]). In this latter study, 5-HT blocked Kv1.2 currents in layer V pyramidal neurons; the authors concluded the effects were mediated by 5-HT~2A~ receptors because of their dense expression. Still, 5-HT~2C~ receptors are also expressed in the frontal cortex, and modulate excitatory activity there ([@R18]). We acknowledge and appreciate that the modulatory activity of 5-HT~2~ receptor subtypes that affects behavior is complex. 5-HT~2~ receptor subtypes may modulate activity of unique Kv1.x channels, and the discovery of 5-HT~2~ receptor subtype expression patterns within discrete neural circuits will likely lead to further elucidation of their individual functions. For example, 5-HT~2A~ receptors are found in the NAc shell and core ([@R169]; [@R186]), but (like 5-HT~2C~) the functions of 5-HT~2A~ receptors in subregions of the NAc are unclear. Additional studies are needed to cull the specific Kv1.x channel subtypes that may associate with 5-HT~2C~ to lead to suppression of addictive behaviors.

Many cell types and many unique afferents are found within the NAc and VTA ([@R232]). Thus, a complete picture must show which cells express 5-HT~2A~, 5-HT~2B~, and 5-HT~2C~ receptors, the relative densities of receptors, and their unique contributions to network activity. Finally, 5-HT~2C~ chemical probes, including both agonists and antagonists, are, with few exceptions, notoriously non-selective ([@R46]; [@R62]; [@R213]). We have found, for example, that the "selective" 5-HT~2C~ agonist, Ro 60-0175, is a potent and efficacious 5-HT~2A~ agonist at the Gα~q~-PLC pathway, and when administered systemically at 3 mg/kg, Ro 60-0175 produces a HTR in C57BL/6J mice (unreported observations; data available upon request). It would be interesting to compare the behavioral and neurochemical effects of Ro 60-0175 directly to the more selective 5-HT~2C~ agonist lorcaserin, as well as to the recently reported selective 5-HT~2A~ agonist 25CN-NBOH ([@R88]; [@R122]) to tease apart contributions of the 5-HT~2~ receptor subtypes more clearly (see the section on testable hypotheses below).

Classic hallucinogens treat addiction {#S11}
=====================================

Literature from the 1950s through the 1970s, as well as modern reports, show that CH have positive effects on substance dependence ([@R26]; [@R27]; [@R87]). Thus, not only do CH appear to be non-addictive, several studies show that they reverse the addictive effects of other psychoactive drugs. CH have been used to alleviate neurotic symptoms by indigenous people for thousands of years ([@R114]), and the discovery of LSD and its psychoactive effects sparked considerable interest in the therapeutic potential of CH. Most work focused on the use of these compounds as an adjunct to psychotherapy. Between 1950 and the mid-1960s, more than 1000 quasi-clinical trials were completed, several dozen books were published, and six international conferences were held providing data on approximately 40,000 patients that had undergone "psychedelic" therapy sessions ([@R114]; [@R218]). In the context of the treatment of substance dependence, most studies focused on the use of LSD for the treatment of alcoholism (for reviews, see [@R4]; [@R26]; [@R86]; [@R114]; [@R174]). These studies examined both single, high-dose, and repeated low-dose designs, follow-up periods of several years, control groups, and a total subject pool of well in excessive of 1000 individuals ([@R4]). Between 50% and 70% of the subjects showed reduced drinking or sobriety and/or improved social or professional functioning. Such a treatment effect is exceptional compared to current Food and Drug Administration--approved medications for alcoholism (i.e., disulfiram, naltrexone, and acamprosate). However, the relatively low number of participants in each study, lax designs, and suspect claims led many to question whether accurate conclusions could be made. Nevertheless, results from the six randomized trials of LSD for alcohol dependence that reported drinking outcomes ([@R32]; [@R132]; [@R171]; [@R206]; [@R245]; [@R256]) recently underwent a meta-analysis ([@R158]) that demonstrated consistent treatment effects supporting the efficacy of LSD.

Work with CH largely terminated by the 1970s due to the governmental regulatory response to advocates of the use of these drugs outside of the medical arena. Nonetheless, in the last decade, there has been a resurgence in the study of CH in general, and in the use of CH for the treatment of substance dependence in particular. This recent work has foregone the use of LSD in favor of psilocybin, and has extended our knowledge of the beneficial effects of CH to nicotine dependence ([@R25]; [@R148]). We note that some researchers appreciate that stimulation of 5-HT~2A~ receptors (which are generally what come to mind when people think of CH) may exacerbate substance dependence (as discussed above) and have speculated that profound, rapid, and long-lasting agonist stimulated downregulation of 5-HT~2A~ receptors (i.e., functional antagonism) could be responsible for the anti-addiction effects of CH ([@R26]).

Herein, we have proposed a non-exclusive and empirically testable hypothesis that the beneficial effects of CH for substance dependence are mediated by agonist stimulation of 5-HT~2C~ receptors. If, however, CH were both to stimulate 5-HT~2C~ receptors acutely and result in long-term downregulation of 5-HT~2A~ receptors, this may account for their purported therapeutic effects. Indeed, if CH treat addiction simply by stimulating 5-HT~2C~ receptors, it would likely be preferable to use a selective 5-HT~2C~ receptor agonist instead of CH. Although, others surmise that CH may be effective against addiction because of their psychedelic effects. They can elicit peak or mystical experiences, and afterglow effects, which can alter engrained personality domains such as openness ([@R172]; [@R173]). These effects may be beneficial for psychotherapy and loosening relatively fixed behavioral patterns that underlie addiction.

Despite the potential for CH to treat addiction, it is important to caution that repeated exposure to CH could also chronically alter 5-HT~2C~ receptor expression and/or function, potentially leading to an enhanced susceptibility to addiction via a loss of intrinsic efficacy of 5-HT~2C~ receptors to modulate reward circuitry. Indeed, it does not escape our awareness that use of CH does not render persons immune to drug addiction, and a recent report shows that psilocybin users were significantly more likely to use addictive drugs ([@R120]). Thus, medical supervision, psychological support, and careful preparation to control for set and setting in the context of CH use are likely important requirements to produce therapeutic effects.

Testable hypotheses for unraveling the anti-addictive effects of classic hallucinogens {#S12}
======================================================================================

The literature we have reviewed above suggests a number of experiments that warrant testing in future studies. These experiments would serve to delineate more clearly the role of 5-HT~2~ receptor subtypes underlying the low addiction liability of CH. Morever, they would elucidate our understanding of the mechanisms involved, and the results would provide new testable hypotheses. Among these experiments are: (1) to determine whether recently synthesized compounds such as 25CN-NBOH, which shows ∼90-fold higher selectivity for activating 5-HT~2A~ over 5-HT~2C~, also show higher abuse liabilities than CH (caveat: that first the pharmacology of 25CN-NBOH is assessed at off-targets, e.g., opioid receptors, which would confound conclusions); (2) to determine whether animals with genetic deletion of the 5-HT~2C~ receptor will self-administer CH; (3) to determine the abuse liability of CH in the presence of a selective 5-HT~2C~ receptor antagonist; (4) to determine the precise localization of 5-HT~2C~ receptors in cells of the NAc, with particular emphasis on whether 5-HT~2C~ receptors are expressed on D1-expressing GABAergic MSN of the NAc shell ([@R43]; [@R167]; [@R205]; [@R210])---these MSN are the predominant MSN afferents of the VTA that modulate dopamine release in the NAc ([@R23]); and (5) to determine the nature of 5-HT~2C~-Kv1.x interactions in forebrain regions implicated in addiction. We believe that these experiments would add greatly to the literature, and are enthused to see them completed.

We wish to thank the Communications Office of the Mercer University College of Pharmacy for their professional work to enhance [Figure 2](#F2){ref-type="fig"}. In particular, we wish to thank David Holland and Jennifer Brock for their work on improving the artistic design of the graphic.

**Funding**: The author(s) received no financial support for the research, authorship, and/or publication of this article. However, while the manuscript was under review, Drs. Canal and Murnane received 1R21DA040907-01 from NIDA.

**Declaration of conflicting interests**: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

![Autoradiographs of brain 5-HT~2C~ receptors from mice that overexpress 5-HT~2C~ (5-HT~2C-VGV~) allowing clear observations of 5-HT~2C~ receptor distribution in the brain. Notably, 5-HT~2C~ is densely expressed in the nucleus accumbens (NAc), but not in the dorsal striatum (DStr); the darker the shade, the higher the receptor binding site density. \[^3^H\]Mesulergine (3 nM for eight weeks) or \[^125^I\]DOI (0.14 nM for 48 hours) was used in the presence of spiperone (100 nM) to label 5-HT~2C~ receptors. These sections were part of a set collected by Dr. Canal ([@R203]). All sections labeled with \[^3^H\] Mesulergine or with \[^125^I\]DOI are from the same brain. Pictures from the latter were cropped and pasted to align them vertically.](nihms858830f1){#F1}

![Proposed 5-HT2C anti-cocaine addiction mechanism involving modulation of Kv1.x channels on GABAergic medium spiny neurons (MSN) of the NAc shell.](nihms858830f2){#F2}
